Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. - Wikidata - wikimedia - TriplyDB

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

http://www.wikidata.org/entity/Q30525394

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition T Lymphocyte Migration: An Action Movie Starring the Actin and Associated Actors.The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy Combining radiation and immunotherapy: a new systemic therapy for solid tumors?NKG2D ligands as therapeutic targets Combining radiotherapy and cancer immunotherapy: a paradigm shift The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration The kinematics of cytotoxic lymphocytes influence their ability to kill target cells Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance.CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation.Is tumor (R)ejection by the immune system the "5th R" of radiobiology?NKG2D CARs as cell therapy for cancer.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1 Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes.Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity Current clinical trials testing combinations of immunotherapy and radiation.Radiation as an immunological adjuvant: current evidence on dose and fractionation.Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl Actin cytoskeleton control of the comings and goings of T lymphocytes.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.Confusing signals: recent progress in CTLA-4 biology Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment Optimizing tumor immune response through combination of radiation and immunotherapy.Immunomodulatory effects of radiation: what is next for cancer therapy?Towards precision radiotherapy for use with immune checkpoint blockers.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

P2860

Q26738443-035A9260-D46F-459C-884F-BE65199F09C5 Q26753082-4839423A-876A-4428-B0C8-520321CC7BBB Q26765115-3DAB7DDA-B235-49CA-ACA1-09CADA65EAAE Q26766419-8853025D-81BA-41C9-A034-804D2C17E4C6 Q26774663-7077B92A-5265-44CF-B0C2-21D2B650AFCE Q26783291-AA3D059F-F87D-461C-9344-D99A6666A50C Q26991721-516526E5-819A-4BFF-BCB0-DBE0B44D63BE Q27014888-7956ECF2-9B56-4C88-8148-011667303D5D Q27021428-3825D615-FEF2-44E5-93A4-FC39ECEB015A Q27024106-EAB80CFE-0FFA-4EED-8DD3-AC0889D36909 Q27329768-6A3C9299-1E7B-4C30-89C9-1DB3E47B102B Q27337590-63E0065E-479B-4521-AFA3-2A61FFDE148D Q28066199-03CE79A8-9650-4BA1-BA6A-BECEE9112D13 Q30573918-3CCF5C75-1034-4E45-A2A0-CB6B2EC695A4 Q30605826-4660240E-A284-465A-BE5B-23671A30A8E0 Q33560039-DD45DB78-CB89-4F18-9CC2-B6DB6A7CF547 Q33595873-28AD5486-1B45-488F-94AE-C75E48256488 Q33658400-A1071DFF-AAB3-4138-97F3-38DB831E5881 Q34389948-BEF00711-29FC-4F74-BDD5-1487D612DAA2 Q35828606-81F1007D-C2FB-4511-9C53-C6948A1D79B8 Q35908369-FE07E085-BD42-415A-89A1-856061BAE305 Q36268306-0379BAB4-292F-4F91-BE23-6532713783EC Q36347177-749C8DE0-673F-4856-947F-3F77338886D0 Q36605917-92E0011A-0AB5-49D1-9F19-C2D4BF77C076 Q37085973-604EDA01-BDEC-462C-973D-CEE94DDDD9EF Q37308207-DD1EBC47-DB2B-40E7-B4A9-123EEAB667E4 Q37518395-ED8C0874-D963-4D09-A8F5-12F04C27B1E3 Q37520816-FED6FD40-6904-4C1B-83AA-115D67E0F05D Q37609957-A2DD8736-68A0-462B-9B4F-7EF915C38101 Q38153058-97248E83-AE5E-474D-B258-61C1364A0201 Q38202161-E72D9B15-261E-4CE1-B712-D3EAE448FD23 Q38299845-38DD1EAF-3630-45AA-99D7-2E5A5EE73067 Q38315713-43263DA6-7CC4-4210-8E89-4F595D13B771 Q38413904-622E3968-050E-41CF-B954-D94BE32441D9 Q38447992-CF731097-CE4C-4876-98CD-44650833D630 Q38543250-38D0FB39-79BC-466B-BF61-B8DD2EF0CF94 Q38614781-592D8FE1-B1BA-4F82-92C5-9AA49188907F Q38654155-9815930A-2A20-4ECE-972D-F0F6777DBDE9 Q38656599-B743BC5F-7B89-4B0F-80AC-1D051356C5F2 Q38730881-D6E06770-6079-4F8C-BB96-A8965A56B200

P2860

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

http://www.wikidata.org/entity/Q30525394

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Suppressing T cell motility in ...... py improves antitumor effects.

@ast

Suppressing T cell motility in ...... py improves antitumor effects.

@en

type

label

Suppressing T cell motility in ...... py improves antitumor effects.

@ast

Suppressing T cell motility in ...... py improves antitumor effects.

@en

prefLabel

Suppressing T cell motility in ...... py improves antitumor effects.

@ast

Suppressing T cell motility in ...... py improves antitumor effects.

@en

P1433

Q30525394-657331E4-3ED6-4BAB-BD23-B75984AD5338

P1476

Q30525394-EC7A76A1-057A-4020-8852-10ADF7022840

P2093

Q30525394-23B884AD-B018-4F8D-9890-6F7FB8B8CBEB

Q30525394-3E7BC371-E895-4503-98E3-31E4F38DDF51

Q30525394-4E5187CD-443D-4D67-891A-4255C19864B4

Q30525394-5C2645E9-9D10-4CF2-A40D-4AA9092C81D0

Q30525394-63686886-4740-4E56-8E59-30B359D955B2

Q30525394-7FFB9E84-BAA7-4486-A303-AD287948BC5A

Q30525394-AB4FE40E-B1DF-449C-9F5E-6A9AB868C2B4

Q30525394-F5C27E46-CC9E-47B7-A31F-AFBE14CB99FE

P2860

Q30525394-007D0139-B760-4E4A-AC4E-5C89AA8CEFB8

Q30525394-01E7483C-0BFC-419F-926E-7353FBBA703B

Q30525394-07105441-5121-4E40-95F1-8BA5C10ADDBD

Q30525394-07F5D1C0-1CF7-4E28-B515-CA67EFD23E9A

Q30525394-106ECF86-E961-4150-82BD-99024E508D2D

Q30525394-110DF1E3-7966-4BAB-8F62-FA20903DEE7E

Q30525394-17EBE32F-2766-444E-B10E-30404A6B8BEC

Q30525394-2169698B-8E93-411F-81A0-A7AAA2219B37

Q30525394-221BFA7F-A7D8-4518-9C7E-74B9745CEEC8

Q30525394-22DBB83B-3076-43C7-8DEC-468D9026C6A7

P304

Q30525394-3ACF1CBC-F502-40A7-880E-A8350E860C11

P31

Q30525394-A82798A0-754F-459E-B3DC-E1E8CA164362

P356

Q30525394-E49731BD-CAA8-4AE2-81DF-0A1932024623

P407

Q30525394-DCD2F1DB-0C35-49BD-9B42-C51138C5EC13

P433

Q30525394-EB3D76C8-531F-406C-AE55-E64C672FA8E3

P478

Q30525394-4DF7AE47-DB66-4557-8986-3053EFC31B77

P50

Q30525394-1ACF121D-7AB3-4636-9F7A-11321F43A81D

Q30525394-70F67A87-A3D8-4EC4-A0F8-3E5F59ABFE21

P577

Q30525394-BB0FB994-3B89-4336-9E8A-ACF302812B97

P5875

Q30525394-8A1AF9AC-D686-48E0-BEC4-D0E3CE9AC455

P698

Q30525394-9FD0AEE9-44CC-4DB9-820A-A2F0818C97E2

P932

Q30525394-AC9F40A5-9F2D-4259-9848-BD7E12A25711

P356

P1433

Journal of Clinical Investigation

P1476

Suppressing T cell motility in ...... py improves antitumor effects.

@en

P2093

James S Babb

http://www.w3.org/2001/XMLSchema#string

Julie Huang

http://www.w3.org/2001/XMLSchema#string

Karsten A Pilones

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Ruocco

http://www.w3.org/2001/XMLSchema#string

Mengling Liu

http://www.w3.org/2001/XMLSchema#string

Michael Cammer

http://www.w3.org/2001/XMLSchema#string

Noriko Kawashima

http://www.w3.org/2001/XMLSchema#string

Silvia C Formenti

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Reversal of the TCR stop signal by CTLA-4

Enhancement of antitumor immunity by CTLA-4 blockade

Two-photon imaging of lymphocyte motility and antigen response in intact lymph node

Visualizing dendritic cell networks in vivo

P304

3718-3730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI61931

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Michael L Dustin

P577

2012-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230791137

http://www.w3.org/2001/XMLSchema#string

P698

22945631

http://www.w3.org/2001/XMLSchema#string

P932

3461908

http://www.w3.org/2001/XMLSchema#string